1Peter P, Frank R, Nick G, et al. Sulfonylurea stimulation of in aulin secretion. Diabetes, 2002,51 ( Suppl 3): S368-S376.
2Garratt KN, Brady PA, Haasinger NL, et al. Sulfonylurea drugs increase early motality in patients with diabetes mellitus after direct angioplasty for acute myocardial infaction. J Am Cell Cardiol, 1999,33:119-124.
3Matthaei S, Stumvoll M, Kellerer M, et al. Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev,2000,21:585-618.
4Davis TM, Parsons RW, Broadburst R J, et al. Arrhythmias and mortality after myocardial infaction in diabetic patients: relationship to diabetes treatment. Diabetes Care, 1998,21:637-640.
5Renstrom E, Barg S, Thevenod F, et al. Sul.fonylurea-mediated stimulation of insulin exocytosis via an ATP-sensitive K + channel-independent action. Diabetes, 2002,51 (Suppl 1 ): S33-S36.
6Muller G. The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic suffonylurea drug Amaryl. Mol Med, 2000,6:907-933.
7Dills DG, Schneider J. Glimepiride/Glyburide Research Group. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Horm Metab Res, 1996,28:426-429.
8Muller G. Dynamics of plasma membrane microdomains and cross-talk to the insulin signalling cascade. FEBS Lett, 2002,531: 81-87.
9DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med, 1999,131:281-303.
10Richard A, Michelle S, Phillip B. Oral agents for the treatment of type 2diabetes mellitus: pharmacology, toxicity, and treatment. Ann Emeg Med,2001,38:68-78.
